Mesogastrium Metastasis in Colon Cancer

Colon Cancer Clinical Trial

Official title:

Right Gastroepiploic Mesentery Metastasis in Advanced Colon Cancer Locating at or Close to the Hepatic Flexure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04980287
• Other study ID #: TJ-IRB20210649
• Status: Recruiting
• Start date: January 12, 2021
• Est. completion date: July 19, 2026

Study information

• Verified date: January 2023
• Source: Tongji Hospital
• Contact: Jichao Qin, M.D./Ph.D
• Phone: 008613628683363
• Email: jcqin[@]tjh.thmu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Complete mesocolic excision is currently recognized as a standard procedure for colon cancer. Controversy remains on the presence of right gastroepiploic mesentery metastasis in patients with colon cancer locating at or close to the hepatic flexure. The investigators design this study in order to define the incidence of mesogastrium metastasis and analyse the safety and surgical outcome in these patients who undergo complete mesocolic excision with right gastroepiploic mesentery resection.

Description:

The development of gastrointestinal surgery has passed over three periods: organ resection, radical resection based on vascular blood vessel center and functional radical organ resection based on membrane anatomy. Using high-definition laparoscopy, surgeons could observe the membrane structure that cannot be identified in traditional open surgery. Total mesocolic excision or complete mesocolic excision has been widely recognized in clinical practice. In 2009, hohenberger et al. proposed the concept of complete mesocolic excision (CME) for the first time. They retrospectively analyzed the data of 1329 patients with colon cancer who underwent radical resection from 1978 to 2002. They found that the 5-year local recurrence rate decreased from 6.5% to 3.6%, and the 5-year survival rate increased from 82.1% to 89.1%.In 2015, Jianping Gong further introduced the anatomy of mesentery, and highlighted that the radical operation of gastrointestinal tumor should not only complete the traditional D2 or D3 lymph node dissection, but also need the complete excision of the mesentery within the right presumed metastatic tumor cells existingbearing range. On the one hand, its clinical significance lies in reducing intraoperative severe complications; On the other hand, better radical operation and due to avoiding "cancer leakage". Complete mesocolic excision is currently recognized as a standard procedure for colon cancer. According to the theory of membrane anatomy, the right gastroepiploic mesentery and the mesentery of colon are independent which act as separate envelope. As right gastroepiploic mesentery metastases were classified as distant metastaticmetastasis, radical resection of colon cancer under CME combined with resection of the right gastroepiploic mesentery is not appropriate for patients with colon cancer locating at or close to the hepatic flexure. . Currently, literatures on the surgical methods and boundary of lymph node dissection for colon cancer are all retrospective studies, and lack of RCT evidence. Controversy remains on the presence of mesogastrium metastasis in patients with colon cancer locating at or close to the hepatic flexure. Therefore, the following questions remain to be addressed: will cancer malignant tumors located locating at or close to hepatic flexure or transverse colon close to flexures metastasize to the right gastroepiploic mesentery (including but not limiting No.6 lymph nodes)? The No.6 lymph node metastasis of No.6 lymph nodes in the patients with colon cancer locating at the hepatic flexure have been reported, but whether the " No.6 lymph nodes " were mixed with lymph nodes in the colon mesentery was unknown. The investigators design this study in order to define the incidence of mesogastrium metastasis in colon cancer locating at or close to the hepatic flexure, and analyse analyze the safety and surgical outcome in these patients undergoing complete mesocolic excision plus right gastroepiploic mesentery resection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 19, 2026
• Est. primary completion date: July 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 75 years
• American Society of Anesthesiologists (ASA) score I to III
• A biopsy proven histological diagnosis of colorectal carcinoma
• Preoperative staging cT2-4aN0M0 or cTanyN+M0
• tumor located at hepatic flexure or transverse colon close to flexures
• Undergoing complete mesocolic excision with right gastric mesentery resection
• Patients have to be aware of the aim of the trial, and have signed the informed consent.

Exclusion Criteria:

• Synchronous colorectal carcinoma
• Clinical evidence of metastasis
• History of colorectal cancer or other malignant tumors
• Preoperative staging cT1N0 or cT4bNany
• Emergency procedure

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms
• Neoplasm Metastasis

Locations

Country	Name	City	State
China	Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Jichao Qin

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	metastasis rate	the incidence of gastric mesentery metastasis	an average of 1 year
Secondary	intraoperative complication	intraoperative complication of complete mesocolic excision plus right gastroepiploic mesentery resection	an average of 1 year
Secondary	postoperative complication	postoperative complication of complete mesocolic excision plus right gastroepiploic mesentery resection	an average of 1 year
Secondary	3-year DFS	3-year disease free survival	an average of 3 years